Assessing Cosopt Switch Patients

Phase 4

Completed

• Conditions: Ocular Hypertension; Open-Angle Glaucoma; Exfoliation Syndrome; Glaucoma, Pigmentary

• Registration Number: NCT00273442
• Lead Sponsor: Pharmaceutical Research Network

Brief Summary

To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11
• Study First Submitted: 2006-01-06
• Study First Submitted QC: 2006-01-06
• Study First Posted: 2006-01-09
• Study Completion: 2007-04
• Status Verified: 2008-11
• Last Update Submitted: 2008-11-18
• Last Update Posted: 2008-11-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension
• the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM
• visual acuity should be 20/200 or better in each eye

Exclusion Criteria

• contraindications to study drugs
• anticipated change in systemic hypotensive therapy during the trial
• use of any corticosteroids by any route in the three months immediately prior to Visit 2

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (5)

Little Rock Eye Clinic; 🇺🇸 Little Rock, Arkansas, United States

Omni Eye Services; 🇺🇸 Atlanta, Georgia, United States

Glaucoma Consultants & Center for Eye Research; 🇺🇸 Mt. Pleasant, South Carolina, United States

Mark J. Weiss, MD; 🇺🇸 Tulsa, Oklahoma, United States

Midwest Eye Center; 🇺🇸 Bourbonnais, Illinois, United States